ノルエピネフリンは,ヒトの孤立した冠動脈動脈小動脈のβ2受容体媒介の拡張を誘発する
Dong Sun1, An Huang, Seema Mital
1Department of Physiology, New York Medical College, Valhalla 10595, USA.
Circulation
|July 31, 2002
まとめ
ノルエピネフリンは,ヒトの冠動脈を,滑らかな筋肉のβ2受容体を通して膨らませる. この研究は,ヒトの心臓の循環における血流の調節に関与する特定のアドレノ受容体を明らかにしています.
科学分野:
- 心血管生理学 心血管の生理学
- 薬理学 薬理学とは
- 人間の生理学 人間生理学
背景:
- 人間の冠動脈循環のノルエピネフリン媒介の調節におけるアドレノ受容体の役割については,さらなる解明が必要である.
- これらのメカニズムを理解することは,心血管疾患の管理に不可欠です.
研究 の 目的:
- ノルエピネフリン (NE) に対するヒトの冠動脈反応に関与する特定のアドレノ受容体の特徴を特定する.
- 孤立したヒトの冠動脈小動脈および小動脈におけるNE効果を媒介するシグナル伝達経路を調査する.
主な方法:
- 隔離されたヒトの冠動脈小動脈と,心臓が膨張した小さな動脈をカヌル化して研究した.
- NEに対する容器の反応は,様々な受容器阻害剤および阻害剤の存在または欠如によって評価されました.
- 濃度-反応曲線は,NEおよび他の血管活性剤のために生成されました.
主要な成果:
- ノルエピネフリン (NE) は,ヒトの冠動脈小動脈と小動脈の濃度依存の拡張を誘発した.
- これらの膨張はベータ2受容体アンタゴニスト (プロプラノロール,ブトキサミン) によって完全に阻害されたが,ベータ1阻害剤やNO合成酵素阻害剤によって完全に阻害されなかった.
- NEへの収縮は,小数の血管のサブセットで観察され,アルファ1受容体阻害剤によって抑制されました.
結論:
- 孤立したヒトの冠動脈小動脈と小動脈は,主に血管の滑らかな筋肉に位置するβ2-アドレノ受容体を通して,NEに反応して膨張します.
- これらの発見は,ヒトの冠動脈循環におけるNEの作用メカニズムの理解を高める.
さらに関連する動画
09:47Measurement of Endothelium-Dependent Vasorelaxation in the Mouse Thoracic Aorta Using Tensometric Small Volume Chamber Myography
Published on: August 12, 2022
3.5K
07:53Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
Published on: June 16, 2022
3.3K
関連する概念動画
Adrenergic Receptors (Adrenoceptors): Classification
4.8K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
4.8K
Adrenergic Receptors: ɑ Subtype
2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Adrenergic Receptors: β Subtype
3.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.8K
Sympathetic Signaling
3.3K
Sympathetic signaling, a vital part of the autonomic nervous system, plays a crucial role in mobilizing the body's resources in response to stress or emergencies. It involves the transmission of nerve impulses from sympathetic preganglionic fibers to postganglionic fibers. This results in the release of specific neurotransmitters and activation of adrenergic receptors.
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
3.3K
Antihypertensive Drugs: Action of β1 Blockers
2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
Antihypertensive Drugs: Types of β-Blockers
2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
